FutureWork Playbook Pioneering srRNA Technology to Revolutionize Access to Critical Care
Replicate Bioscience are designing and delivering RNA-based treatments that revolutionize the practice of medicine In this episode, Natalie talks with immunologist Nathaniel Wang, CEO of Replicate Biosciences.
You may have heard a lot about RNA vaccines over the past year so Natalie take this opportunity to ask Nathaniel to explain the science behind the technology and how it has become a breakthrough in providing critical care to many.
What we discussed:
- The history of Replicate Bioscience, how they were founded, and the work they were doing on RNA research prior to the COVID-19 pandemic
- Nathaniel explains what RNA is and why it’s so important, especially as it relates to COVID-19
- RNA isn’t a new technology, but the challenge was scaling it
- How the development and implementation of this technology has impacted accessibility to medical care
- How drugs are currently made and why RNA is such a gamechanger
- The existing concerns around synthetic technology and why some people may get sick after getting the COVID-19 vaccine
- Nathaniel talks about the clinical trial process, regulatory hurdles, and the importance of having varying experts across many fields on their team
- An overview of some of the new products that Replicate Bioscience is excited about
- How Nathaniel got series A funding from ATP and why they’re excited to partner with Replicate Bioscience
- The future of Replicate Bioscience
Helpful Links:
Nathanial Wang LinkedIn
Be sure to connect with us and reach out with any questions/concerns:
LinkedIn: www.linkedin.com/company/gunderson-dettmer
Twitter: www.twitter.com/GundersonLaw
Gunderson Dettmer Website: www.gunder.com
This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.